CDA | Evidence Driven
CDA | Evidence Driven

dostarlimab

Details

Files
Generic Name:
dostarlimab
Project Status:
Active
Therapeutic Area:
Endometrial cancer
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
Jemperli
Project Line:
Reimbursement Review
Project Number:
PC0381-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open04-Jul-24
Call for patient/clinician input closed30-Aug-24
Submission received15-Aug-24
Submission accepted29-Aug-24
Review initiated30-Aug-24
Draft CADTH review report(s) provided to sponsor for comment18-Nov-24
Deadline for sponsors comments27-Nov-24
CADTH review report(s) and responses to comments provided to sponsor19-Dec-24
Expert committee meeting (initial)08-Jan-25
Draft recommendation issued to sponsor-
Draft recommendation posted for stakeholder feedback-
End of feedback period-

Files

Patient and Clinician Group Input View PDF
Last Updated : November 18, 2024